- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
Novartis scraps sale of assets including COVID-19 hopeful to Indis's Aurobindo Pharma
Apr 02, 2020
India will ship nearly 1,000 tonnes of paracetamol raw material to Europe
May 06, 2020
Eye Drops Market is expected to reach US$ 23,788.4 million by 2030
Aug 09, 2023
Drug Discovery Services Market is expected to reach US$ 56,783.29 million by 2030
Nov 17, 2023
NORTH AMERICA DRY EYE PRODUCT MARKET IS ANTICIPATED TO GROW WITH A CAGR OF 5.0% FROM 2019 TO 2027 , according to Business Market Insights
Jan 28, 2021
Shorla Pharma Closes $8.3M Series A Funding Round
Jun 03, 2020
POULTRY VACCINES Market Report: Unlocking Growth Potential and Addressing Challenges
Nov 28, 2025